Evidence map›Paper›PMID 26989128›Full record

ReviewNeuro-oncology2016

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Jaishri O Blakeley, Stephen Joel Coons, John R Corboy, Nancy Kline Leidy, Tito R Mendoza, Jeffrey S Wefel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Neuropsychological Practice in the Oncology Setting.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2018
    Article
  17. Article
  18. Response Assessment in Neuro-Oncology Clinical Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jaishri O BlakeleyJohns Hopkins University, Departments of Neurology, Neurosurgery and Oncology, Baltimore, Maryland (J.O.B.); Critical Path Institute, 1730 E. River Road, Tucson, Arizona (S.J.C.); University of Colorado School of Medicine, Denver Veterans Affairs Medical Center, 12631 East 17th Avenue B185, Aurora, Colorado (J.R.C.); Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, Maryland (N.K.L.); University of Texas MD Anderson Cancer Center, 1515 Holcombe Bld., Houston, Texas (T.R.M., J.S.W.).
Stephen Joel CoonsJohns Hopkins University, Departments of Neurology, Neurosurgery and Oncology, Baltimore, Maryland (J.O.B.); Critical Path Institute, 1730 E. River Road, Tucson, Arizona (S.J.C.); University of Colorado School of Medicine, Denver Veterans Affairs Medical Center, 12631 East 17th Avenue B185, Aurora, Colorado (J.R.C.); Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, Maryland (N.K.L.); University of Texas MD Anderson Cancer Center, 1515 Holcombe Bld., Houston, Texas (T.R.M., J.S.W.).
John R CorboyJohns Hopkins University, Departments of Neurology, Neurosurgery and Oncology, Baltimore, Maryland (J.O.B.); Critical Path Institute, 1730 E. River Road, Tucson, Arizona (S.J.C.); University of Colorado School of Medicine, Denver Veterans Affairs Medical Center, 12631 East 17th Avenue B185, Aurora, Colorado (J.R.C.); Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, Maryland (N.K.L.); University of Texas MD Anderson Cancer Center, 1515 Holcombe Bld., Houston, Texas (T.R.M., J.S.W.).
Nancy Kline LeidyJohns Hopkins University, Departments of Neurology, Neurosurgery and Oncology, Baltimore, Maryland (J.O.B.); Critical Path Institute, 1730 E. River Road, Tucson, Arizona (S.J.C.); University of Colorado School of Medicine, Denver Veterans Affairs Medical Center, 12631 East 17th Avenue B185, Aurora, Colorado (J.R.C.); Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, Maryland (N.K.L.); University of Texas MD Anderson Cancer Center, 1515 Holcombe Bld., Houston, Texas (T.R.M., J.S.W.).
Tito R MendozaJohns Hopkins University, Departments of Neurology, Neurosurgery and Oncology, Baltimore, Maryland (J.O.B.); Critical Path Institute, 1730 E. River Road, Tucson, Arizona (S.J.C.); University of Colorado School of Medicine, Denver Veterans Affairs Medical Center, 12631 East 17th Avenue B185, Aurora, Colorado (J.R.C.); Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, Maryland (N.K.L.); University of Texas MD Anderson Cancer Center, 1515 Holcombe Bld., Houston, Texas (T.R.M., J.S.W.).
Jeffrey S WefelJohns Hopkins University, Departments of Neurology, Neurosurgery and Oncology, Baltimore, Maryland (J.O.B.); Critical Path Institute, 1730 E. River Road, Tucson, Arizona (S.J.C.); University of Colorado School of Medicine, Denver Veterans Affairs Medical Center, 12631 East 17th Avenue B185, Aurora, Colorado (J.R.C.); Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, Maryland (N.K.L.); University of Texas MD Anderson Cancer Center, 1515 Holcombe Bld., Houston, Texas (T.R.M., J.S.W.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.

Indexed as

Clinical Trials as TopicOutcome Assessment, Health CareQuality of LifeAnimalsBrain NeoplasmsGliomaHumansSurveys and Questionnairesclinical outcome assessmentclinical trialsendpointsmalignant glioma

Identifiers

PMID26989128
PMCPMC4795998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.